Direct Acting Antivirals for Hepatitis C (HCV) — Coverage Criteria
Customize your policy alerts
Sign up for all Alaska Medicaid policy alerts
Know when Alaska Medicaid releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization and quantity limit policy for FDA‑approved direct acting antiviral (DAA) medications for treatment of chronic hepatitis C virus (HCV) infection for Alaska Medicaid members, including approval criteria, authorized regimens, and renewal requirements.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Initial Authorization Criteria
Covered when ALL of the following are met for initial authorization:
All items must be documented in the PA request or medical record
Renewal and Extended Duration Criteria
Renewal/extended duration covered when ALL of the following are met:
Applies to renewal/extension requests
Testing required for certain regimens
Regimen Authorization and Specialist Restriction
Regimen selection rules and specialist restrictions:
Refer to the policy table for exact genotype and treatment‑experience mappings
Specialist restriction and FDA‑approved indication required
Requests for treatment of acute hepatitis C infection are excluded from coverage and will be denied. The policy’s denial criteria explicitly list a request for diagnosis of acute hepatitis C infection as a basis for denial.
Combination therapy including ribavirin is contraindicated in patients who are pregnant and in men whose partners are pregnant because of the risk of birth defects and fetal death. Documentation of pregnancy risk and appropriate counseling must be considered and provided when ribavirin exposure is possible; absence of such consideration is a trigger for denial.
Agents that are FDA-approved but for which clinical benefit has not been established will not be approved under this policy. In addition, use of a non-preferred agent without a documented clinical contraindication to preferred agents or without trial of an appropriate preferred option is not supported and may be denied.
What Providers Must Do / Authorization Requirements
Prior Authorization Required
Prior authorization is required for Direct Acting Antivirals (DAAs) for chronic hepatitis C. Approval requires meeting the policy clinical criteria and submission of required documentation. Prescribers must perform a patient readiness assessment and submit a signed patient attestation of treatment compliance.
- Prior authorization required for all DAA requests
- Prescriber must perform patient readiness assessment and submit signed attestation
- Approval contingent on meeting documented clinical criteria
Preferred Agent Requirement / Step Therapy
Alaska Medicaid requires use of preferred HCV agents (for example, Mavyret) when a medically appropriate preferred agent is available. A non-preferred agent will only be approved if there is a documented clinical reason (e.g., intolerance, contraindication, or prior treatment failure) supporting medical necessity for the non-preferred product.
- Preferred agent requirement: trial or contraindication documentation required before non-preferred agent will be approved
- Example preferred agent: Mavyret (when medically appropriate and available)
Required Documentation with Prior Authorization
Authorization requests must include documentation of chronic HCV diagnosis and supporting clinical information. Incomplete requests will be non-clinically denied after 7 calendar days if requested information is not provided.
- Required with PA: diagnosis of chronic HCV, HCV genotype, viral resistance status (when applicable), hepatic status (Child-Pugh score), and HCV viral load
- Required with PA: documentation of prior HCV therapies, dates, completion status or reason for discontinuation, and resistance data if available
- Required with PA: HBV screening (HBsAg and anti-HBc); if HCV/HIV co-infected, include CD4 count, HIV viral load, and HIV regimen
- Required with PA: signed patient attestation of readiness/compliance and prescriber agreement to obtain SVR12 HCV RNA
Triggers for Denial
Requests will be denied under specified conditions including clinical and documentation deficiencies. If incomplete information is submitted, prescribers have 7 calendar days to respond to avoid non-clinical denial.
- Request for acute hepatitis C infection — DENY
- Request for a non-preferred agent when a medically appropriate preferred agent is available — DENY
- Request for a preferred agent for duration exceeding the FDA‑approved duration for the indication — DENY
- Patient readiness not assessed or signed attestation not included — DENY
- Active substance dependency without referral for treatment — DENY
- Patient Child‑Pugh score > 6 (Class B or C) without management by or consultation with a liver disease specialist — DENY
- Concomitant medications that counteract DAA efficacy or create safety risk — DENY
- Patient age 12–18 years not managed by or in consultation with a liver disease specialist — DENY
- Request for a non-preferred agent when a less expensive, medically appropriate preferred agent is available — DENY
- Incomplete PA requests: prescriber has 7 calendar days to provide requested information or the PA will be non-clinically denied
Definitions and Key Terms
Background and Clinical Context
Direct acting antivirals (DAAs) are oral agents approved to treat chronic hepatitis C (HCV) infection across genotypes. Treatment selection depends on HCV genotype, prior treatment experience, presence and degree of cirrhosis (Child‑Pugh class), and resistance‑associated substitutions when applicable. Prior authorization is required and approval is contingent on documentation of chronic HCV diagnosis, genotype and resistance testing when required, hepatic status (including Child‑Pugh score), prior HCV therapy history, and a signed patient readiness attestation. Prescribers are expected to monitor HCV RNA during therapy and to maintain HCV RNA at 12 weeks post‑therapy (SVR12) documentation in the medical record.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.